GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility

Estrogen receptor (ESR1) drives growth in the majority of human breast cancers by binding to regulatory elements and inducing transcription events that promote tumor growth. Differences in enhancer occupancy by ESR1 contribute to the diverse expression profiles and clinical outcome observed in breast cancer patients. GATA3 is an ESR1-cooperating transcription factor mutated in breast tumors; however, its genomic properties are not fully defined. In order to investigate the composition of enhancers involved in estrogen-induced transcription and the potential role of GATA3, we performed extensive ChIP-sequencing in unstimulated breast cancer cells and following estrogen treatment. We find that GATA3 is pivotal in mediating enhancer accessibility at regulatory regions involved in ESR1-mediated transcription. GATA3 silencing resulted in a global redistribution of cofactors and active histone marks prior to estrogen stimulation. These global genomic changes altered the ESR1-binding profile that subsequently occurred following estrogen, with events exhibiting both loss and gain in binding affinity, implying a GATA3-mediated redistribution of ESR1 binding. The GATA3-mediated redistributed ESR1 profile correlated with changes in gene expression, suggestive of its functionality. Chromatin loops at the TFF locus involving ESR1-bound enhancers occurred independently of ESR1 when GATA3 was silenced, indicating that GATA3, when present on the chromatin, may serve as a licensing factor for estrogen-ESR1-mediated interactions between cis-regulatory elements. Together, these experiments suggest that GATA3 directly impacts ESR1 enhancer accessibility, and may potentially explain the contribution of mutant-GATA3 in the heterogeneity of ESR1+ breast cancer.

[1]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[2]  Frank R. Lin,et al.  Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. , 2002, Molecular cell.

[3]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Strausberg,et al.  Mutation of GATA3 in human breast tumors , 2004, Oncogene.

[5]  R. Strausberg,et al.  Mutation of GATA 3 in human breast tumors , 2004 .

[6]  Clifford A. Meyer,et al.  Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1 , 2005, Cell.

[7]  M. Groudine,et al.  Proximity among distant regulatory elements at the beta-globin locus requires GATA-1 and FOG-1. , 2005, Molecular cell.

[8]  Debashis Ghosh,et al.  Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. , 2005, Cancer research.

[9]  Clifford A. Meyer,et al.  Genome-wide analysis of estrogen receptor binding sites , 2006, Nature Genetics.

[10]  K. Horwitz,et al.  Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. , 2006, Cancer research.

[11]  Charles M Perou,et al.  Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas , 2007, Breast Cancer Research.

[12]  Yi Zhang,et al.  Genes associated with breast cancer metastatic to bone. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Zena Werb,et al.  GATA-3 Maintains the Differentiation of the Luminal Cell Fate in the Mammary Gland , 2006, Cell.

[14]  F. Stossi,et al.  Whole-Genome Cartography of Estrogen Receptor α Binding Sites , 2007, PLoS genetics.

[15]  K. Pienta,et al.  A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. , 2007, Molecular cell.

[16]  Marie-Liesse Asselin-Labat,et al.  Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation , 2007, Nature Cell Biology.

[17]  Georgia Chenevix-Trench,et al.  Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors , 2008, Breast Cancer Research and Treatment.

[18]  G. Blobel,et al.  Exchange of GATA factors mediates transitions in looped chromatin organization at a developmentally regulated gene locus. , 2008, Molecular cell.

[19]  E. Liu,et al.  Regulation of Estrogen Receptor-mediated Long Range Transcription via Evolutionarily Conserved Distal Response Elements* , 2008, Journal of Biological Chemistry.

[20]  J. Kolesar,et al.  Chemoprevention of breast cancer. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[21]  Clifford A. Meyer,et al.  FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription , 2008, Cell.

[22]  E. Liu,et al.  An Oestrogen Receptor α-bound Human Chromatin Interactome , 2009, Nature.

[23]  H. Stunnenberg,et al.  ChIP‐Seq of ERα and RNA polymerase II defines genes differentially responding to ligands , 2009, The EMBO journal.

[24]  Michael D. Wilson,et al.  ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. , 2009, Methods.

[25]  J. Kench,et al.  A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes , 2009, Oncogene.

[26]  A. Visel,et al.  ChIP-seq accurately predicts tissue-specific activity of enhancers , 2009, Nature.

[27]  Christel Krueger,et al.  Cohesin Is Required for Higher-Order Chromatin Conformation at the Imprinted IGF2-H19 Locus , 2009, PLoS genetics.

[28]  Nathaniel D. Heintzman,et al.  Histone modifications at human enhancers reflect global cell-type-specific gene expression , 2009, Nature.

[29]  Pieter Wesseling,et al.  Receptor conversion in distant breast cancer metastases , 2010, Breast Cancer Research.

[30]  G. Kreiman,et al.  Widespread transcription at neuronal activity-regulated enhancers , 2010, Nature.

[31]  R. Young,et al.  Histone H3K27ac separates active from poised enhancers and predicts developmental state , 2010, Proceedings of the National Academy of Sciences.

[32]  N. D. Clarke,et al.  Integrative model of genomic factors for determining binding site selection by estrogen receptor-α , 2010, Molecular systems biology.

[33]  J. Stamatoyannopoulos,et al.  Chromatin accessibility pre-determines glucocorticoid receptor binding patterns , 2011, Nature Genetics.

[34]  Wing-Kin Sung,et al.  Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state , 2011, Molecular systems biology.

[35]  J. Carroll,et al.  FOXA1 is a critical determinant of Estrogen Receptor function and endocrine response , 2010, Nature Genetics.

[36]  V. Theodorou,et al.  Oestrogen receptor–co‐factor–chromatin specificity in the transcriptional regulation of breast cancer , 2011, The EMBO journal.

[37]  O. Kallioniemi,et al.  Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer , 2011, The EMBO journal.

[38]  Leighton J. Core,et al.  A Rapid, Extensive, and Transient Transcriptional Response to Estrogen Signaling in Breast Cancer Cells , 2011, Cell.

[39]  O. Kallioniemi,et al.  Dual role of FoxA 1 in androgen receptor binding to chromatin , androgen signalling and prostate cancer , 2011 .

[40]  C. Glass,et al.  Reprogramming Transcription via Distinct Classes of Enhancers Functionally Defined by eRNA , 2011, Nature.

[41]  M. Groudine,et al.  Functional and Mechanistic Diversity of Distal Transcription Enhancers , 2011, Cell.

[42]  Raymond K. Auerbach,et al.  Extensive Promoter-Centered Chromatin Interactions Provide a Topological Basis for Transcription Regulation , 2012, Cell.

[43]  Rory Stark.  Differential Oestrogen Receptor Binding is Associated with Clinical Outcome in Breast Cancer , 2012, RECOMB.

[44]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[45]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .